54820-92-7

Usage

Uses

Used in Pharmaceutical Industry:
5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE is used as a potential pharmaceutical agent for its structural features and possible biological activities. Its unique chemical composition may allow for the development of new drugs or therapeutic agents, pending further research and investigation into its properties and effects.
Used in Agrochemical Industry:
In the agrochemical sector, 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE may serve as a precursor or active ingredient in the development of new agrochemical products. Its potential applications could include the creation of pesticides, herbicides, or other agricultural chemicals, leveraging its structural attributes to target specific biological processes or pests.
Note: The specific applications and reasons for using 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE in the pharmaceutical and agrochemical industries are not detailed in the provided materials. The uses listed are speculative based on the compound's structural features and potential for biological activity, highlighting the need for further research to determine its exact applications and benefits.

Upstream product

• 60-34-4 methylhydrazine 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 89943-20-4 2-cyano-3-ethoxythiocrotonamide 
• 1187-11-7 acetylmalonodinitrile 
• 5515-16-2 2-(methoxyethylidene)propanedinitrile 
• 7339-53-9 methyl hydrazine hydrochloride 

Downstream Products

• 1026602-36-7 N-(4-Cyano-2,5-dimethyl-2H-pyrazol-3-yl)-2-propoxy-benzamide 
• 1607479-48-0 C₂₂H₂₅N₉O 
• 1030377-75-3 1,3-dimethyl-6-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}-1H-pyrazolo[3,4-d]pyrimidine 
• 1072895-86-3 4,6-dichloro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidine 
• 773140-12-8 N-(4-cyano-2,5-dimethyl-2H-pyrazol-3-yl)-2-fluoro-benzamide 
• 168464-48-0 C₁₉H₂₁N₇O₂S 

Relevant academic research and scientific papers

The pyrazole derivative or its salt in a pharmaceutical composition containing them

PROBLEM TO BE SOLVED: To provide a novel compound and a pharmaceutical composition useful for treatment and/or prevention of HIV virus infections.SOLUTION: Provided is a pyrazole derivative represented by the general formula (I) or a salt thereof (in the

A Michael Equilibration Model to Control Site Selectivity in the Condensation toward Aminopyrazoles

A Michael equilibration model is presented to provide for site-selective pyrazole condensations between alkoxyacrylonitriles and hydrazines. Both pyrazole isomers were accessed with high selectivity by employment of kinetically or thermodynamically controlled conditions. Substrate scope and identification of Michael intermediates, as well as competitive pathways, support the presented mechanistic proposal. Sandmeyer derivatization provided site-selective access to fully substituted pyrazoles.

1,3-disubstituted-4-aminopyrazolo [3, 4-d] pyrimidines, a new class of potent inhibitors for phospholipase D

Phospholipase D enzymes cleave lipid substrates to produce phosphatidic acid, an important precursor for many essential cellular molecules. Phospholipase D is a target to modulate cancer-cell invasiveness. This study reports synthesis of a new class of phospholipase D inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules were synthesized and used to perform initial screening for the inhibition of purified bacterial phospholipase D, which is highly homologous to the human PLD1. Initially tested with the bacterial phospholipase D enzyme, then confirmed with the recombinant human PLD1 and PLD2 enzymes, the molecules presented here exhibited inhibition of phospholipase D activity (IC50) in the low-nanomolar to low-micromolar range with both monomeric substrate diC4PC and phospholipid vesicles and micelles. The data strongly indicate that these inhibitory molecules directly block enzyme/vesicle substrate binding. Preliminary activity studies using recombinant human phospholipase Ds in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicate inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment. This study reports synthesis of a new class of PLD inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules exhibited inhibition of human recombinant PLD activity (IC 50) in the low-nanomolar to low-micromolar range with monomeric substrate diC4PC and phospholipid vesicles and micelles. Preliminary activity studies using recombinant human PLDs in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicates inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment.

Structure-activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents

The structure-activity relationship of phenylpyrazole derivative 1 was investigated for the development of novel anti-HIV agents. Initial efforts revealed that the diazenyl group can be replaced by an aminomethylene group. In addition, we synthesized various derivatives by the reductive amination of benzaldehydes with 5-aminopyrazoles and carried out parallel structural optimization on the benzyl group and the pyrazole ring. This optimization led to a six-fold more potent derivative 32j than the lead compound 1, and this derivative has a 3′,4′-dichloro-(1,1′-biphenyl)-3-yl group.

PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Fomula I]

Substituted diazepan orexin receptor antagonists

The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

HCV INHIBITING BI-CYCLIC PYRIMIDINES

The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for pre

Bicyclicpyrimidones and their use to treat diseases

The present invention is directed to dihydropyrimidones having formula I or II and methods of using them to induce mitotic arrest, thereby making them useful as anti-cancer agents and other diseases that can be treated by inducing mitotic arrest.

Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones

A series of 6-phenylpyrazolo[3,4-d]pyrimidones is described which are specific inhibitors of cGMP specific (type V) phosphodiesterase. Enzymatic and cellular activity as well as in vivo oral antihypertensive activity are evaluated. A n-propoxy group at the 2-position of the phenyl ring is necessary for activity. A series of products substituted at the 5-position in addition to the 2-n-propoxy was prepared and evaluated. This position can accommodate many unrelated groups. Amino derivatives were very potent but lacked metabolic stability. Substitution by carbon-linked small heterocycles provided both high levels of activity and stability. Cellular activity very often correlated with in vivo activity. Among the compounds, 1,3-dimethyl-6- (2-propoxy-5-methanesulfonamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin- 4-one (38) and 1-ethyl-3-methyl-6-(2-propoxy-5-(4-methylthiazol-2-yl)phenyl)- 1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one (59) displayed outstanding in vivo activities at 5 mg/kg/os and good metabolic stabilities.

6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

Novel 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-ones, useful in treating cardiovascular disease, are prepared by reacting a 5-amino-1H-pyrazole-4-carboxamide with heterocyclylcarboxaldehyde or by reacting a 5-amino-1H-pyrazole-4-carbonitrile with a heterocyclylcarboxamidine, followed by diazotization and hydrolysis of the resulting 4-amino-6-heterocyclyl-pyrazolo[3,4-d]pyrimidine.